miércoles, 7 de octubre de 2026

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· June 9, 2026

Snowflake stock gets a bold AI call from Wall Street

View original at finance.yahoo.com

Snowflake stock gets a bold AI call from Wall Street Snowflake (SNOW) wants to convince Wall Street its next act is larger than cloud data storage…

Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

Snowflake aims to be seen by investors as one of the primary platforms big firms will use to organise, regulate and activate their data for AI agents
60% confidence
Snowflake's full-year fiscal 2027 product revenue is projected at $5.84 billion, representing 31% growth
60% confidence
Snowflake has 779 clients with trailing 12-month product revenue greater than $1 million
60% confidence
Snowflake struck a five-year, $6 billion deal with Amazon Web Services for AI infrastructure, Graviton processors, product integrations and business AI workload migrations
60% confidence
Snowflake has a Buy rating with a $300 price target, implying approximately 22.5% upside from the June 2 closing price of $244.82
60% confidence
Enterprises will need Snowflake's platform before AI can go from demos to the day-to-day activities of corporations
60% confidence

Data points we hold from this source

Snowflake Inc. · stock price	244.82 USD
Snowflake Inc. · backlog	9.21 USD

Lo que sabemos · la inteligencia detrás de esta página

En vivo desde el sustrato

Lo que estamos viendo

Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs

Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.

Nuestra lectura de los datos ›

Señales que seguimos

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patrones que observamos ›

Donde las fuentes discrepan

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

Señalamos los conflictos abiertamente ›

Verificado recientemente

✓ Verificado con la fuente original

4,986

hechos rastreados a su fuente — y señalamos los que no se sostienen.

101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados

Consulta estos datos → isubstrate.com